CN1583792A - Vitellus immune globulin for preventing prawn virus, tis preparing method and use thereof - Google Patents
Vitellus immune globulin for preventing prawn virus, tis preparing method and use thereof Download PDFInfo
- Publication number
- CN1583792A CN1583792A CN 200410020691 CN200410020691A CN1583792A CN 1583792 A CN1583792 A CN 1583792A CN 200410020691 CN200410020691 CN 200410020691 CN 200410020691 A CN200410020691 A CN 200410020691A CN 1583792 A CN1583792 A CN 1583792A
- Authority
- CN
- China
- Prior art keywords
- igy
- prawn
- virus
- prawns
- shrimp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000238557 Decapoda Species 0.000 title claims abstract description 107
- 241000700605 Viruses Species 0.000 title claims abstract description 56
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 18
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 21
- 244000144977 poultry Species 0.000 claims abstract description 15
- 241000696962 White spot syndrome virus Species 0.000 claims abstract description 13
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 108010013639 Peptidoglycan Proteins 0.000 claims abstract description 10
- 241000411851 herbal medicine Species 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000003674 animal food additive Substances 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 6
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 6
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 5
- 238000003287 bathing Methods 0.000 claims abstract description 4
- 239000002131 composite material Substances 0.000 claims abstract description 4
- 230000017448 oviposition Effects 0.000 claims abstract description 4
- 230000002238 attenuated effect Effects 0.000 claims abstract 2
- 238000005507 spraying Methods 0.000 claims abstract 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 19
- 108010000912 Egg Proteins Proteins 0.000 claims description 19
- 235000013345 egg yolk Nutrition 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 235000013601 eggs Nutrition 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 9
- 241000701447 unidentified baculovirus Species 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 230000005965 immune activity Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 241000272814 Anser sp. Species 0.000 claims description 2
- 241000318927 Shrimp white spot syndrome virus Species 0.000 claims description 2
- 210000003981 ectoderm Anatomy 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 210000003716 mesoderm Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 241001149925 Fenneropenaeus indicus Species 0.000 claims 3
- 241000272525 Anas platyrhynchos Species 0.000 claims 1
- 241000530454 Litopenaeus schmitti Species 0.000 claims 1
- 241000121184 Monodon Species 0.000 claims 1
- 241000927735 Penaeus Species 0.000 claims 1
- 241000392970 Prunus serrulata Species 0.000 claims 1
- 235000014001 Prunus serrulata Nutrition 0.000 claims 1
- 241000907645 Sicyonia ingentis Species 0.000 claims 1
- 241001275767 Stomatopoda Species 0.000 claims 1
- 241000272534 Struthio camelus Species 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000003053 immunization Effects 0.000 abstract description 10
- 238000002649 immunization Methods 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000003975 animal breeding Methods 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 230000008076 immune mechanism Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000238552 Penaeus monodon Species 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009313 farming Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000238017 Astacoidea Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 101150010086 VP24 gene Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 206010034203 Pectus Carinatum Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 241000271039 Agkistrodon Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000995704 Fenneropenaeus chinensis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- 241001124325 Marsupenaeus japonicus Species 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000009364 mariculture Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于生物技术领域,涉及到水产动物养殖技术领域,特别涉及到一种防治对虾病毒病的卵黄免疫球蛋白(IgY)及其制备方法。其特征是将对虾白斑综合症病毒类的一种或多种灭活毒株/减毒毒株/基因亚单位免疫原/核酸免疫原制成单一抗原或复合抗原,以产蛋禽类作为生物反应器,免疫获得抗对虾白斑综合症特异性IgY,该IgY可单独或与肽聚糖、益生素及中草药组合共同作为饲料添加剂、药用浸浴剂或虾池泼洒剂的活性成分应用于对虾病害防治。本发明的效果和益处是该IgY通过被动免疫机制发挥作用,直接抑杀病毒,增强虾体免疫力,在预防和治疗对虾白斑综合症具有效果显著、安全、环保、使用方便等优点。The invention belongs to the field of biotechnology, relates to the technical field of aquatic animal breeding, and in particular relates to a yolk immunoglobulin (IgY) for preventing and treating prawn virus disease and a preparation method thereof. It is characterized in that one or more inactivated strains/attenuated strains/gene subunit immunogens/nucleic acid immunogens of the prawn white spot syndrome virus are made into a single antigen or a composite antigen, and egg-laying poultry is used as a biological reaction Specific IgY against white spot syndrome of prawns can be obtained by immunization, and this IgY can be used alone or in combination with peptidoglycan, prebiotics and Chinese herbal medicines as feed additives, medicinal bathing agents or active ingredients of shrimp pond spraying agents to apply to prawn diseases Prevention and treatment. The effect and benefit of the present invention are that the IgY plays a role through the passive immune mechanism, directly suppresses and kills the virus, enhances the immunity of the shrimp body, and has the advantages of significant effect, safety, environmental protection, convenient use and the like in the prevention and treatment of white spot syndrome of prawns.
Description
技术领域technical field
本发明属于生物技术领域,涉及到水产动物养殖技术领域,特别涉及到一种防治对虾病毒病的卵黄免疫球蛋白(IgY)及其制备方法,此种IgY可以用作饲料添加剂或药物浸浴剂或泼洒剂的活性成分防治对虾白斑综合症。The invention belongs to the field of biotechnology, relates to the technical field of aquatic animal breeding, and in particular relates to a yolk immunoglobulin (IgY) for preventing and treating prawn virus disease and a preparation method thereof. The IgY can be used as a feed additive or a medicine bathing agent or the active ingredient of the splashing agent to control the white spot syndrome of prawns.
背景技术Background technique
我国的对虾养殖起步于20世纪70年代末,养殖生产技术的不断改进与完善,使之迅速成为海水养殖业的支柱产业之一,但是随着对虾人工养殖企业化的发展,人们盲目地进行高密度放养,加上养殖的生态环境不断恶化等原因,使得对虾疾病特别是对虾病毒性病害成了阻碍这一产业发展的重要因素。1993~1994年对虾病毒病肆虐我国大江南北、横扫各对虾养殖场,造成了70%以上的养殖对虾死亡。据不完全统计,由此造成的直接经济损失达数百亿元,严重影响了沿海地区渔业经济的发展。在造成养殖对虾大面积死亡的病因研究中,人们发现病毒病往往是罪魁祸首,已经报道的病毒病不下15种之多,且不断有新的病毒病被发现和报道。根据《自然》杂志发表地一份研究报告,应用新的定量方法取得地研究结果表明在自然水体中,病毒颗粒地数量比人们预期的要多得多,高达每升2.5×108个。my country's prawn farming started in the late 1970s. The continuous improvement and perfection of aquaculture production technology made it quickly become one of the pillar industries of the mariculture industry. The density of stocking, coupled with the continuous deterioration of the ecological environment for farming, has made shrimp diseases, especially viral diseases of shrimps, an important factor hindering the development of this industry. From 1993 to 1994, prawn virus disease ravaged all over my country and swept across all prawn farms, causing more than 70% of the cultured prawns to die. According to incomplete statistics, the direct economic loss caused by this amounted to tens of billions of yuan, seriously affecting the development of fishery economy in coastal areas. In the study of the etiology of large-scale mortality of cultured prawns, it was found that viral diseases are often the culprit. There are no less than 15 kinds of viral diseases that have been reported, and new viral diseases are constantly being discovered and reported. According to a research report published in the "Nature" magazine, the results obtained by applying a new quantitative method show that the number of virus particles in natural water bodies is much higher than expected, as high as 2.5×10 8 per liter.
白斑综合症是对虾养殖的最重要疾病之一,其病原体为一类白斑综合症病毒(WSSV-type,White Spot Syndrome Virus group)。包括白斑杆状病毒(WSBV),皮下及造血组织坏死杆状病毒(HHNBV),日本对虾核型杆状病毒(RV-PJ),系统性外胚层、中胚层杆状病毒(SEMBV),无包涵体对虾病毒(NOSV)。该病毒感染力强,被感染的对虾在一周内死亡率高达90~100%。在白斑综合症的防治上,主要采取预防为主的措施:一方面通过改造养虾池,改善养殖环境,提高养殖技术起到间接预防的作用;另一方面主要使用肽聚糖、微生物多糖、维生素C、中草药、益生素、蝇蛆,提高虾体自身免疫力,以期增强对虾抵抗病毒侵染的能力,但尚无特效的治疗药物制剂防治白斑综合症。White spot syndrome is one of the most important diseases in prawn farming, and its pathogen is a kind of white spot syndrome virus (WSSV-type, White Spot Syndrome Virus group). Including white spot baculovirus (WSBV), subcutaneous and hematopoietic baculovirus (HHNBV), shrimp nuclear baculovirus (RV-PJ), systemic ectoderm and mesoderm baculovirus (SEMBV), noninclusion Somatic Shrimp Virus (NOSV). The virus is highly contagious, and the mortality rate of infected prawns is as high as 90-100% within a week. In the prevention and treatment of white spot syndrome, prevention-oriented measures are mainly adopted: on the one hand, by transforming shrimp ponds, improving the breeding environment, and improving the breeding technology to play an indirect preventive role; on the other hand, mainly using peptidoglycan, microbial polysaccharide, Vitamin C, Chinese herbal medicine, probiotics, and fly maggots can improve the self-immunity of shrimp, in order to enhance the ability of shrimp to resist virus infection, but there is no specific therapeutic drug preparation to prevent and treat white spot syndrome.
上述这些药物制剂主要通过提高对虾的非特异性免疫能力,增强对虾抵抗病毒侵染的能力,但针对病毒本身束手无策。肽聚糖和微生物多糖的活性易受菌种、发酵条件等因素的影响而限制了其应用;维生素C还原态极不稳定,药效发挥受到影响;中草药资源非常有限,药效缓慢,毒副作用有待进一步研究,且受原料品质、加工方法、配伍比例等因素的制约;益生素(活菌制剂)易受外界条件影响,在加工贮藏时易失活,进入消化道后亦会被消化液所灭活,难有足够数量的有益菌发挥作用,活菌的菌种种类也较少。These above-mentioned pharmaceutical preparations mainly enhance the ability of the shrimp to resist virus infection by improving the non-specific immunity of the shrimp, but they are helpless against the virus itself. The activity of peptidoglycan and microbial polysaccharides is easily affected by factors such as strains and fermentation conditions, which limits their application; the reduced state of vitamin C is extremely unstable, and the efficacy of the medicine is affected; the resources of Chinese herbal medicine are very limited, the efficacy of the medicine is slow, and the side effects are toxic. Further research is needed, and it is restricted by factors such as raw material quality, processing methods, and compatibility ratios; probiotics (live bacteria preparations) are easily affected by external conditions, and are easily inactivated during processing and storage, and will also be absorbed by the digestive juice after entering the digestive tract. Inactivated, it is difficult to have a sufficient number of beneficial bacteria to play a role, and there are fewer types of live bacteria.
IgY是一种与哺乳动物IgG结构类似的禽源抗体,具有较高的免疫活性,50ng/ml含量仍能被检测出有特异性活性,其性能稳定,有较强的耐热性,65℃条件下,IgY的活性至少可保持24h以上,经巴氏杀菌后活性保持不变;耐酸耐碱范围宽,pH4.0~11.0时稳定,并可通过微囊化进一步提高其稳定性,且无毒、无残留、无副作用,绿色环保。根据需求采用不同抗原对禽类进行免疫,即可产生针对该抗原的特异性IgY,而且利用禽类生产特异性IgY具有可规模化生产、成本低、特异性抗体含量高(100~400mg/鸡蛋)及安全性好等优点,再经干燥处理加工制成粉剂便可添加于饲料或饵料中,使用方便,且宜于推广。IgY is an avian-derived antibody similar in structure to mammalian IgG. It has high immune activity, and its specific activity can still be detected at a content of 50ng/ml. It has stable performance and strong heat resistance. Under certain conditions, the activity of IgY can be maintained for at least 24 hours, and the activity remains unchanged after pasteurization; the range of acid and alkali resistance is wide, and it is stable at pH 4.0-11.0, and its stability can be further improved by microencapsulation, and there is no Toxic, no residue, no side effects, green and environmental protection. According to the needs, different antigens are used to immunize poultry to produce specific IgY against the antigen, and the use of poultry to produce specific IgY has the advantages of large-scale production, low cost, high content of specific antibodies (100-400mg/egg) and It has the advantages of good safety, etc., and then it can be added to feed or bait after being dried and processed into powder, which is convenient to use and suitable for popularization.
IgY可与相应抗原发生特异性结合,从而抑制或改变该抗原的状态或活性。口服IgY可使机体获得被动免疫,IgY可封闭病毒吸附易感细胞受体的表位,从而阻止病毒吸附和穿入细胞内增值,因此限制了病毒在细胞、组织之间扩散以及在血流中蔓延。而免疫禽蛋具有多种免疫增强因子,机体摄取后,可发挥协同作用,增强机体的非特异性免疫能力,提高抗病力。IgY can specifically bind to the corresponding antigen, thereby inhibiting or changing the state or activity of the antigen. Oral administration of IgY can enable the body to obtain passive immunity. IgY can block the epitope of the virus-adsorbed susceptible cell receptor, thereby preventing the virus from adsorbing and penetrating into the cell to proliferate, thus limiting the spread of the virus between cells and tissues and in the bloodstream. spread. Immune poultry eggs have a variety of immune enhancing factors, which can play a synergistic effect after the body ingests them, enhance the body's non-specific immunity, and improve disease resistance.
由于IgY及免疫禽蛋具有上述优良特性,即克服目前免疫增强剂等药物对病毒实际杀灭作用不大,实际生产应用受限的缺点,可从根源上预防和治疗由白斑综合症病毒这种病原体引发的对虾病毒病。Because IgY and immune poultry eggs have the above-mentioned excellent characteristics, that is, to overcome the shortcomings of current immune enhancers and other drugs that have little actual killing effect on the virus and limited practical production and application, it can prevent and treat the disease caused by white spot syndrome virus from the root. Shrimp viral diseases caused by pathogens.
目前,已公开的WO03070258、KR2003069506-A和WO2004004764-A1专利文献虽然提供了一种使用卵黄免疫球蛋白预防或治疗对虾白斑综合症的方法,但上述发明依然存在以下不足:At present, although published WO03070258, KR2003069506-A and WO2004004764-A1 patent documents provide a method for preventing or treating prawn white spot syndrome using yolk immunoglobulin, the above invention still has the following deficiencies:
1.对虾白斑综合症的病原体为一类病毒,不同地域不同宿主感染的白斑病病毒存在差异,仅选择白斑综合症病毒的一种制备抗原,免疫产生的IgY种类单一,仅对该病毒抗原起作用,无法应用于其它病毒株引起的感染,实际应用范围缩小,抑杀病毒效果减弱。1. The pathogen of prawn white spot syndrome is a type of virus. There are differences in the white spot disease virus infected by different hosts in different regions. Only one kind of white spot syndrome virus is selected to prepare the antigen. It cannot be applied to infections caused by other virus strains, the practical application range is narrowed, and the effect of suppressing and killing viruses is weakened.
2.未使用白斑综合症病毒基因或其抗原决定簇的基因制成核酸免疫原,由此带来诸如免疫禽类产生抗体效价不均一,产量不稳定,实际应用效果降低等缺点。2. The nucleic acid immunogen is made without using the white spot syndrome virus gene or its antigenic determinant gene, which brings disadvantages such as uneven antibody titer produced by immunized poultry, unstable yield, and reduced practical application effect.
3.仅以IgY作为防治对虾白斑综合症的唯一活性成分,不仅添加剂量加大,而染毒对虾因免疫力的下降导致其它致病微生物的乘虚而入,但该IgY却不能有效抑制水体或虾体内部存在的这些致病微生物,无法达到最佳治疗效果。3. Only IgY is used as the only active ingredient for the prevention and treatment of white spot syndrome in prawns. Not only the dosage is increased, but the immunity of the infected prawns is reduced, which leads to the entry of other pathogenic microorganisms, but the IgY cannot effectively inhibit the water body or These pathogenic microorganisms existing inside the shrimp body cannot achieve the best therapeutic effect.
发明内容Contents of the invention
本发明的目的是提供一种防治对虾白斑综合症的卵黄免疫球蛋白(IgY),并且进一步完善该IgY的制备方法,将其作为饲料添加剂、药用浸浴剂或虾池泼洒剂的主要活性成分应用于对虾病害防治,达到抑杀病毒和增强虾体免疫功能的双重效果,显著降低对虾染毒几率,提高成活率,解决目前在防治对虾白斑综合症方面尚无特效治疗药物制剂的问题。The object of the present invention is to provide a kind of yolk immunoglobulin (IgY) of preventing and treating prawn white spot syndrome, and further improve the preparation method of this IgY, use it as the main activity of feed additive, medicinal bathing agent or shrimp pond splashing agent The ingredients are used in the prevention and control of prawn diseases to achieve the dual effects of inhibiting and killing viruses and enhancing the immune function of prawns, significantly reducing the probability of prawn infection, improving the survival rate, and solving the problem that there is no specific drug preparation for the prevention and treatment of prawn white spot syndrome.
本发明的目的是通过如下技术方案来实现:The purpose of the present invention is to realize through following technical scheme:
1.抗原的制备1. Antigen Preparation
以WSBV作为白斑综合症病毒类的代表株详述其抗原制备过程:Taking WSBV as the representative strain of white spot syndrome virus, the antigen preparation process is described in detail:
(1)WSBV灭活毒株的制备(1) Preparation of WSBV inactivated strain
取健康无WSBV感染的螯虾,清洗体表,在0.01%的高锰酸钾溶液中浸泡5min,无菌水冲洗,酒精棉球消毒头胸甲与腹部交界处。制备螯虾原代细胞,用全培液轻轻均匀重悬,接种到培养瓶或培养板,27℃培养过夜,待用。另取感染WSBV的对虾组织,无菌过滤获得WSBV病毒液,于健康螯虾第三、四腹节进行肌肉注射(60~120μl/只)。感染4~6天后,剥取感染螯虾肌肉组织,以L-15培养基为匀浆缓冲液,提取病毒。选取铺展均匀、状态良好的细胞,按1/10比例加入新鲜制备的病毒感染液,孵育1h,用L-15洗涤细胞3次,加入全培液,于27℃继续培养后收获病毒液,15%NaCl灭活病毒液18~24h,于4℃或-20℃保存。Take healthy crayfish without WSBV infection, wash the body surface, soak in 0.01% potassium permanganate solution for 5 minutes, rinse with sterile water, and disinfect the junction of the carapace and abdomen with alcohol cotton balls. Prepare crayfish primary cells, gently and evenly resuspend them with whole culture medium, inoculate into culture flasks or culture plates, culture overnight at 27°C, and set aside. Another WSBV-infected shrimp tissue was collected, and the WSBV virus liquid was obtained by sterile filtration, and intramuscularly injected into the third and fourth abdominal segments of healthy crayfish (60-120 μl/head). After 4 to 6 days of infection, the muscle tissue of the infected crayfish was stripped, and the L-15 medium was used as a homogenization buffer to extract the virus. Select cells that spread evenly and in good condition, add freshly prepared virus infection solution at a ratio of 1/10, incubate for 1 hour, wash cells with L-15 for 3 times, add full culture solution, continue culturing at 27°C and harvest virus solution, 15 %NaCl inactivated virus solution for 18-24 hours, and stored at 4°C or -20°C.
(2)WSBV基因亚单位免疫原的制备(2) Preparation of WSBV gene subunit immunogen
将病虾的头胸甲取下,去除眼、附肢,加入等体积TN(Tris-NaCl)缓冲液,经高速组织匀浆器12000r/min匀浆5min。匀浆液经5000g离心1h,取上清,经8400g离心20min,再取上清30000g离心1h,取沉淀,加入3~5倍的TN缓冲液重新悬浮,置于15~16%蔗糖密度梯度顶端,经75000g离心2h,收集病毒层1ml,用TN缓冲液稀释,再经8400g离心0.5h,取上清,用等量TN缓冲液重新悬浮,即得纯化病毒。以上离心均在4℃进行。设计并合成引物,提取WSBV中国株(GeneBank登录号AF332093)的基因组DNA作为模板,通过PCR扩增分别克隆出VP24,VP26,VP28基因,亚克隆至载体pUC118的多克隆位点上,得到VP24,VP26,VP28基因的重组克隆质粒,然后分别与表达质粒pGEX-2T连接,转化感受态细胞BL21,筛选阳性菌落。挑取阳性单菌落,于LB培养基中37℃过夜培养,取1/50或1/100菌液转移至含有Amp的5L液体培养基,振摇至A(OD)550=0.4~0.6,加入1.5mlIPTG(1M)诱导表达,1~4h后,离心收集菌体,SDS-PAGE及Western Blot检测表明诱导产生目的蛋白,用谷胱苷肽活化的Sepharose4B亲和层析柱纯化融合蛋白,测定纯化蛋白的浓度,于-20℃保存备用。Remove the carapace of the diseased shrimp, remove the eyes and appendages, add an equal volume of TN (Tris-NaCl) buffer, and homogenize for 5 minutes with a high-speed tissue homogenizer at 12000 r/min. The homogenate was centrifuged at 5000g for 1h, the supernatant was taken, centrifuged at 8400g for 20min, then the supernatant was centrifuged at 30000g for 1h, the precipitate was taken, resuspended by adding 3-5 times of TN buffer, and placed at the top of the 15-16% sucrose density gradient. After centrifugation at 75,000 g for 2 h, 1 ml of the virus layer was collected, diluted with TN buffer, and then centrifuged at 8,400 g for 0.5 h, and the supernatant was taken, resuspended with an equal amount of TN buffer to obtain purified virus. All centrifugation was performed at 4°C. Design and synthesize primers, extract the genomic DNA of the Chinese strain of WSBV (GeneBank accession number AF332093) as a template, clone the VP24, VP26, and VP28 genes by PCR amplification, and subclone them into the multiple cloning site of the vector pUC118 to obtain VP24, The recombinant cloning plasmids of VP26 and VP28 genes were connected with the expression plasmid pGEX-2T respectively, transformed into competent cells BL21, and positive colonies were screened. Pick a single positive colony and culture overnight at 37°C in LB medium, transfer 1/50 or 1/100 of the bacterial solution to 5L liquid medium containing Amp, shake until A(OD) 550 =0.4~0.6, add 1.5ml of IPTG (1M) induced expression, after 1-4 hours, centrifuged to collect the bacteria, SDS-PAGE and Western Blot detection showed that the target protein was induced, and the fusion protein was purified with glutathione-activated Sepharose4B affinity chromatography column, and the purification was determined. The protein concentration was stored at -20°C for future use.
(3)核酸免疫原的制备(3) Preparation of nucleic acid immunogen
如(2)所述方法获得的VP24,VP26,VP28基因,分别与表达质粒pVAX1连接,转化感受态细胞DH5α,筛选阳性菌落。大量提取重组质粒,以Sepharose-CL4B柱层析纯化质粒,以鲎试剂法检测质粒DNA中所含的细菌内毒素,将内毒素含量控制在小于20EU/mg质粒的范围之内,于无菌PBS或无菌水中4℃或-20℃保存备用。The VP24, VP26, and VP28 genes obtained by the method described in (2) were respectively connected to the expression plasmid pVAX1, transformed into competent cells DH5α, and positive colonies were screened. A large number of recombinant plasmids were extracted, the plasmids were purified by Sepharose-CL4B column chromatography, and the bacterial endotoxin contained in the plasmid DNA was detected by the Limulus reagent method, and the endotoxin content was controlled within the range of less than 20EU/mg plasmid, in sterile PBS Or store in sterile water at 4°C or -20°C for later use.
2.禽类免疫2. Poultry Immunization
采用上述方法制备的单一抗原或复合抗原,与福氏完全佐剂或福氏不完全佐剂分别等量混合后,分别对待开产或新开产的健康无病鸡进行初免和加强免疫,共计三次,14天后每隔3天采血1次,测定抗体效价,当达到log211以上时,收集免疫蛋,置4℃保存。The single antigen or compound antigen prepared by the above method is mixed with Freund's complete adjuvant or Freund's incomplete adjuvant respectively in equal amounts, and the healthy disease-free chickens to be laid or newly opened are respectively primed and boosted. A total of three times, after 14 days, blood was collected every 3 days to measure the antibody titer. When it reached log 2 11 or more, the immunized eggs were collected and stored at 4°C.
以上免疫方法和注射频率可根据实际情况适当调整和变化;亦可用上述同样的免疫技术,采用上述抗原,分别对产蛋母鸭或母鹅或火鸡或鸵鸟等不同产蛋禽类进行免疫,获得相应的IgY。The above immunization methods and injection frequency can be appropriately adjusted and changed according to the actual situation; the same immunization technique as above can also be used to immunize different egg-laying poultry such as laying ducks or gooses or turkeys or ostriches with the above-mentioned antigens to obtain Corresponding IgY.
3.具有免疫活性生物制剂的制备3. Preparation of biological agents with immunological activity
(1)特异性IgY的分离纯化(1) Separation and purification of specific IgY
当免疫禽蛋达一定数量后,用0.2~0.5%的新洁尔灭或高锰酸钾水溶液洗净蛋壳表面,再用5%碘酊消毒,最后用75%的酒精脱碘两次。打蛋机打碎免疫蛋,分离卵黄。用灭菌水或缓冲液将具有免疫活性的卵黄液稀释6~10倍,NaOH调pH至5~5.2,于4℃下静置12~18h,离心分离收获上清液,(NH4)2SO4溶液盐析,静置数小时后,乙醇沉淀或硫酸钠沉淀获得IgY粗体液,Sephadex G-200柱层析纯化浓缩粗提液。When the number of immunized poultry eggs reaches a certain amount, wash the eggshell surface with 0.2-0.5% bromogeramine or potassium permanganate aqueous solution, then disinfect with 5% tincture of iodine, and finally deiodine twice with 75% alcohol. The egg beater breaks the immune eggs and separates the yolk. Dilute the immunocompetent egg yolk liquid 6-10 times with sterilized water or buffer solution, adjust the pH to 5-5.2 with NaOH, let it stand at 4°C for 12-18 hours, and centrifuge to harvest the supernatant, (NH 4 ) 2 The SO 4 solution was salted out, and after standing for several hours, the crude IgY liquid was obtained by ethanol precipitation or sodium sulfate precipitation, and the crude extract was purified by Sephadex G-200 column chromatography and concentrated.
(2)免疫活性全蛋粉/卵黄粉/抗体粉的制备(2) Preparation of immune active whole egg powder/yolk powder/antibody powder
将具有免疫活性的全蛋液或卵黄液或纯化IgY溶液搅拌乳化成乳液,采用喷雾干燥或冷冻干燥法制成粉末状。Whole egg liquid or egg yolk liquid or purified IgY solution with immune activity is stirred and emulsified into an emulsion, and spray-dried or freeze-dried to make powder.
本发明的效果和益处是,应用本技术方案制备出的抗对虾白斑综合症的特异性IgY直接作用于对虾白斑综合症的病原体,发挥特异性抑制作用,克服肽聚糖、益生素、中草药等制剂的使用对于病毒本身并无杀灭作用的缺点;本发明又以实际应用的剂型和施药方式设计为口服给料,浸泡虾体,泼洒虾池多种方式相结合的路线,因此对于未染毒的对虾、已染毒的对虾及养殖虾池均有预防感染,抑杀病毒,净化水质,改善环境的特点,进而使得该发明具有作用直接、治本断源、效果明显的优点。The effect and benefit of the present invention are that the specific IgY against prawn white spot syndrome prepared by applying the technical scheme directly acts on the pathogen of prawn white spot syndrome, exerts a specific inhibitory effect, and overcomes peptidoglycan, prebiotics, Chinese herbal medicine, etc. The use of preparation does not have the shortcoming that kills effect to virus itself; Poisoned prawns, poisoned prawns and cultured shrimp ponds all have the characteristics of preventing infection, suppressing and killing viruses, purifying water quality, and improving the environment, so that the invention has the advantages of direct effect, permanent cure and obvious effect.
特别需要指出的是应用白斑综合症病毒的不同病毒株制成的复合抗原获得的特异性IgY是一种多克隆抗体,它可以对多种不同的病原体同时产生抑杀作用,因此大大提高了对虾抗感染的能力,复合抗原实验组对虾成活率可达95~100%,单一抗原实验组对虾成活率90~93%,由于不同地域不同宿主感染的白斑综合症病毒存在差异,使用复合抗原制备的特异性IgY用量少、成本低、效果尤为显著。What needs to be pointed out in particular is that the specific IgY obtained by using the compound antigen made by different strains of white spot syndrome virus is a polyclonal antibody, which can simultaneously produce inhibitory and killing effects on a variety of different pathogens, thus greatly improving the immunity of prawns. Anti-infection ability, the survival rate of prawns in the compound antigen test group can reach 95-100%, and the survival rate of prawns in the single-antigen test group is 90-93%. Due to the differences in the white spot syndrome virus infected by different hosts in different regions, the compound antigen prepared The dosage of specific IgY is small, the cost is low, and the effect is particularly remarkable.
而通过白斑综合症病毒基因或其抗原决定簇的基因制成的核酸免疫原,免疫获得的特异性IgY产量大且稳定,每只蛋含150~200mg的IgY,抗体效价均一,且最高可达1:1024,因此进一步提高了对虾的抗病能力,生产成本亦大大降低。And the nucleic acid immunogen made by the white spot syndrome virus gene or its antigenic determinant gene, the specific IgY yield obtained by immunization is large and stable, each egg contains 150-200mg of IgY, the antibody titer is uniform, and the highest can be obtained up to 1:1024, thus further improving the disease resistance of prawns and greatly reducing the production cost.
再有药物组合物中除了使用特异性卵黄抗体粉或含有该卵黄抗体的蛋黄粉或全蛋粉,还添加了益生素或肽聚糖或中草药等活性成分,多种免疫增强剂的协同作用,彻底阻断各种致病微生物的入侵,增强虾体体质,激活机体非特异性免疫防御机能,增强其抗病防病能力。Furthermore, in addition to using specific egg yolk antibody powder or egg yolk powder or whole egg powder containing the egg yolk antibody, active ingredients such as prebiotics, peptidoglycan or Chinese herbal medicines are added to the pharmaceutical composition, and the synergistic effect of various immune enhancers, Completely block the invasion of various pathogenic microorganisms, enhance the physique of shrimp, activate the body's non-specific immune defense function, and enhance its ability to resist and prevent diseases.
本发明制备的抗对虾白斑综合症特异性IgY又是一种独特的纯天然生物制剂,使用安全、无毒副作用;绿色环保、无药残;同时,它完全不会诱发抗药菌株的产生,亦不会杀灭有益菌造成“菌群失调”。而对虾属低等无脊椎动物,特异性抗原/抗体免疫反应机制的缺乏,致使其仅能通过血细胞的吞噬等简单途径而非产生免疫球蛋白的方式抵御外来侵害,本发明制备的IgY即为一种IgG类的免疫球蛋白,通过发挥被动免疫机制来防治对虾病毒病,因此间接供给对虾免疫球蛋白,弥补对虾存在的免疫机能缺陷,达到抑杀病毒及增强虾体免疫力的双重效果,显著降低对虾感染病毒的几率,促进对虾生长繁殖,进而解决对虾养殖业的燃眉之急,填补对虾病害防治药物缺乏的空白。The anti-prawn white spot syndrome specific IgY prepared by the present invention is a unique pure natural biological preparation, which is safe to use, has no toxic and side effects, is green and environmentally friendly, and has no drug residues; meanwhile, it will not induce the generation of drug-resistant strains at all, It will not kill beneficial bacteria and cause "flora imbalance". And prawns belong to lower invertebrates, lack of specific antigen/antibody immune response mechanism, so that it can only resist external invasion through simple ways such as phagocytosis of blood cells instead of producing immunoglobulin, and the IgY prepared by the present invention is An IgG-type immunoglobulin, which prevents and treats shrimp virus diseases by exerting a passive immune mechanism, thus indirectly supplies shrimp immunoglobulins to make up for the immune function defects of shrimps, and achieves the dual effects of inhibiting virus killing and enhancing shrimp immunity. Significantly reduce the probability of prawn infection with viruses, promote the growth and reproduction of prawns, and then solve the urgent needs of the prawn farming industry and fill the gap in the lack of prawn disease control drugs.
具体实施方式Detailed ways
实施例1Example 1
制备螯虾原代细胞Preparation of Crawfish Primary Cells
取健康无WSBV感染的螯虾,清洗体表,在0.01%的高锰酸钾溶液中浸泡5min,无菌水冲洗,酒精棉球消毒头胸甲与腹部交界处。用无菌注射器吸取2~3mL抗凝剂(0.14mol/L NaCl,0.1mol/L葡萄糖,30mmol/L柠檬酸,26mmol/L柠檬酸钠,10mmol/L EDTA,pH4.6),心窦采血,抗凝剂与血淋巴液混匀离心,1500r/min离心10min,弃上清,沉淀用L-15培养基润洗2次,用全培液(15%犊牛血清、100U/ml青霉素及100μg/ml链霉素的L-15培养液),轻轻均匀重悬淋巴细胞,接种至培养瓶或培养板,27℃培养过夜,待用。Take healthy crayfish without WSBV infection, wash the body surface, soak in 0.01% potassium permanganate solution for 5 minutes, rinse with sterile water, and disinfect the junction of the carapace and abdomen with alcohol cotton balls. Draw 2-3mL anticoagulant (0.14mol/L NaCl, 0.1mol/L glucose, 30mmol/L citric acid, 26mmol/L sodium citrate, 10mmol/L EDTA, pH4.6) with a sterile syringe, and collect blood from the sinus , anticoagulant and hemolymph were mixed and centrifuged, centrifuged at 1500r/min for 10min, the supernatant was discarded, the precipitate was rinsed twice with L-15 medium, and washed with whole culture solution (15% calf serum, 100U/ml penicillin and 100 μg/ml streptomycin in L-15 medium), gently and uniformly resuspend lymphocytes, inoculate into culture flasks or culture plates, culture overnight at 27°C, and set aside.
实施例2Example 2
目的基因克隆Target gene cloning
PCR法扩增获得VP28基因,测序结果表明,该基因含有615个核苷酸,GeneBamk中已有不同来源的WSSV的序列片段同源性为100%。The VP28 gene was amplified by PCR method, and the sequencing results showed that the gene contained 615 nucleotides, and the homology of sequence fragments of WSSV from different sources in GeneBamk was 100%.
实施例3Example 3
蛋白诱导表达protein induced expression
SDS-PAGE电泳检测结果显示结果表明,带重组质粒pGEX-2T的菌株在分子量为24KDa,26KDa,28KDa的位置上分别产生一条特异蛋白质条带,其表达量均占细菌总蛋白质量的40%以上,而对照菌株中均无此相应蛋白质条带产生。The results of SDS-PAGE electrophoresis showed that the strain carrying the recombinant plasmid pGEX-2T produced a specific protein band at the molecular weight of 24KDa, 26KDa, and 28KDa respectively, and the expression amount accounted for more than 40% of the total bacterial protein. , while no corresponding protein band was produced in the control strain.
实施例4Example 4
重组蛋白分离纯化Separation and purification of recombinant protein
用PBS平衡Sepharose4B亲和层析柱的pH值,取菌体裂解物25ml,离心去除细胞碎片,用吸管取上清,加入亲和凝胶柱,让液体流出弃去;待样品液面刚好与柱顶平齐时,加入25ml PBS;而后加入谷胱苷肽洗脱液2.5ml(Glutathion Elution Buffer,谷胱苷肽10mmol/L,pH8.0 Tris-HCl50mmol/L),室温下作用10min后收集流出的液体;重复洗脱4次,收集洗脱液。Use PBS to balance the pH value of the Sepharose4B affinity chromatography column, take 25ml of bacterial lysate, centrifuge to remove cell debris, take the supernatant with a pipette, add the affinity gel column, let the liquid flow out and discard; When the top of the column is even, add 25ml of PBS; then add 2.5ml of glutathione eluent (Glutathion Elution Buffer, glutathione 10mmol/L, pH8.0 Tris-HCl50mmol/L), act for 10min at room temperature and collect The liquid flowing out; repeat the elution 4 times, and collect the eluate.
实施例5Example 5
免疫接种核酸疫苗Immunization with Nucleic Acid Vaccines
如技术方案所述获得的重组质粒于260nm和280nm下测得其光密度比值为1.9。按1D=50μg计算质粒含量,溶于无菌100μl的PBS中,3周龄罗曼鸡免疫一周前,于鸡胸、鸡后腿肌肉三点肌注射蝮蛇毒100μl/点(20μg/ml溶于生理盐水),并标记,而后于鸡胸、鸡后腿肌肉、皮下、腹腔内及静脉内注射50μg/点,一周后以相同剂量相同位置进行二免,两周后免疫剂量增至60μg/点于相同位置进行三免。The optical density ratio of the recombinant plasmid obtained as described in the technical scheme was 1.9 measured at 260 nm and 280 nm. Calculate the plasmid content according to 1D = 50 μg, dissolve it in 100 μl of sterile PBS, and inject 100 μl/point of Agkistrodon venom into chicken breast and chicken hind leg muscles one week before the immunization of 3-week-old Roman chickens (20 μg/ml dissolved in normal saline ), and marked, and then injected 50 μg/point into the chicken breast, chicken hind leg muscle, subcutaneously, intraperitoneally and intravenously, and performed the second immunization with the same dose and the same position one week later, and increased the immune dose to 60 μg/point at the same position after two weeks Three exemptions.
实施例6Example 6
抗体效价的测定Determination of antibody titer
将来自斑节对虾的WSBV如技术方案所述分别制备单一灭活病毒抗原、基因亚单位抗原、核酸抗原,再用该抗原按技术方案所述的免疫禽类的方法免疫蛋鸡,制备抗对虾白斑综合症的特异性IgY。然后,以从该对虾分离纯化的WSBV为检测抗原,ELISA法检测所制得的抗对虾病毒病特异性IgY的结合效价。结果如下表:Prepare single inactivated virus antigen, gene subunit antigen, and nucleic acid antigen from WSBV from Penaeus monodon as described in the technical scheme, and then use the antigen to immunize laying hens according to the method of immunizing poultry described in the technical scheme to prepare anti-prawn white spot Syndrome-specific IgY. Then, using the isolated and purified WSBV from the prawn as a detection antigen, the binding titer of the prepared anti-prawn virus disease-specific IgY was detected by ELISA. The results are as follows:
IgY 检测用抗原 效价IgY Antigen for Detection Titer
I 1:1024I 1:1024
II 1:512II 1:512
III 1:256III 1:256
IV WSBV 1:256IV WSBV 1:256
V 1:1024V 1:1024
VI 1:512VI 1:512
VII 1:512VII 1:512
I:抗灭活病毒特异性IgYI: anti-inactivated virus-specific IgY
II:抗VP28蛋白特异性IgY V:抗pVAX1-VP28特异性IgYII: Anti-VP28 protein-specific IgY V: Anti-pVAX1-VP28-specific IgY
III:抗VP26蛋白特异性IgY VI:抗pVAX1-VP26特异性IgYIII: Anti-VP26 protein-specific IgY VI: Anti-pVAX1-VP26-specific IgY
IV:抗VP24蛋白特异性IgY VII:抗pVAX1-VP24特异性IgYIV: Anti-VP24 protein-specific IgY VII: Anti-pVAX1-VP24-specific IgY
实施例7Example 7
按技术方案所述灭活毒株的制备方法分别制备WSBV、HHNBV、HHNBV、SEMBV、NOSV灭活毒株,按1∶1∶1∶1∶1的比例混合制成复合抗原,并按技术方案所述的免疫禽类的方法免疫蛋鸡,制备抗对虾白斑综合症特异性IgY。然后分别以WSBV、HHNBV、RV-P、SEMBV、NOSV作为检测抗原,ELISA法检测所制得的抗对虾病毒病特异性IgY的结合效价。结果如下表:Prepare the inactivated strains of WSBV, HHNBV, HHNBV, SEMBV, and NOSV according to the preparation method of the inactivated strains described in the technical scheme, mix them in a ratio of 1:1:1:1:1 to make a composite antigen, and press the technical scheme The method for immunizing poultry immunizes laying hens to prepare anti-prawn white spot syndrome specific IgY. Then WSBV, HHNBV, RV-P, SEMBV and NOSV were used as detection antigens respectively, and the binding titer of the prepared anti-prawn virus disease-specific IgY was detected by ELISA method. The results are as follows:
IgY 检测用抗原 效价IgY Antigen for Detection Titer
WSBV 1:1024
HHNBV 1:1024Hhnbv 1: 1024
抗对虾白斑综合症特against shrimp white spot syndrome
RV-P 1:512RV-P 1: 512
异性IgYHetero-IgY
SEMBV 1:512SEMBV 1:512
NOSV 1:512NOSV 1: 512
实施例8Example 8
将来自斑节对虾的WSBV如技术方法所述制备的基因亚单位疫苗VP28、VP26、VP24按1∶1∶1混合均匀,制备复合抗原,再用该抗原免疫蛋鸡,按技术方案所述制备抗对虾白斑综合症的特异性IgY。然后,以从该对虾分离纯化的WSBV为检测抗原,ELISA法检测所制得的抗对虾病毒病特异性IgY的结合效价为1:1024。Mix the gene subunit vaccines VP28, VP26, and VP24 from Penaeus monodon WSBV prepared as described in the technical method at a ratio of 1:1:1 to prepare a composite antigen, and then use the antigen to immunize laying hens, and prepare as described in the technical plan Specific IgY against white spot syndrome in shrimp. Then, using the WSBV isolated and purified from the prawn as the detection antigen, the binding titer of the prepared anti-prawn virus disease-specific IgY detected by ELISA was 1:1024.
实施例9Example 9
将100尾斑节对虾随机分成10组,其中为一组对照,其它为治疗组,每组20尾,WSBV粗提液于对虾第2和第3腹节间侧面向心浅层肌肉注射,每尾0.05ml,对照组2天后出现死亡现象,3天后死亡率达到100%;治疗组,每日两次饲喂含抗对虾病毒病的特异性IgY饵料,未出现死亡病例,且对治疗组随机抽取6-8尾进行PCR病毒检测,检测结果均为阴性。100 tails of Penaeus monodon were randomly divided into 10 groups, one of which was the control group, and the other was the treatment group, 20 tails in each group, and the crude extract of WSBV was injected intramuscularly into the superficial layer of the heart between the second and third abdominal segments of the prawns. tail 0.05ml, the control group died after 2 days, and the mortality rate reached 100% after 3 days; the treatment group was fed with specific IgY bait containing anti-prawn virus disease twice a day, no death cases occurred, and the treatment group was randomized. 6-8 tails were taken for PCR virus detection, and the test results were all negative.
实施例10Example 10
将来自斑节对虾的WSBV如技术方法所述制备单一灭活病毒抗原,免疫蛋鸡,收获若干鸡蛋,分离获得卵黄液200ml,生理盐水稀释5倍,在1升卵黄液中加入肽聚糖和中草药粉剂各100mg,均匀混合后,浸泡6hm2斑节对虾养殖池,110d后,浸泡卵黄液的虾池的发病率在0~10%之间,而对照虾池(未经卵黄液浸泡)的发病率在90~100%之间。Prepare a single inactivated virus antigen from WSBV from Penaeus monodon as described in the technical method, immunize laying hens, harvest some eggs, separate and obtain 200ml of yolk liquid, dilute it 5 times with normal saline, add peptidoglycan and 100 mg each of Chinese herbal medicine powder, mixed evenly, soaked in 6hm 2 ponds of Penaeus monodon, after 110 days, the incidence rate of shrimp ponds soaked in egg yolk liquid was between 0% and 10%, while that of the control shrimp ponds (not soaked in egg yolk liquid) The incidence rate is between 90 and 100%.
试验池 对照池
虾 养殖 池发 虾 养殖 池发Shrimp Farming Chifa Shrimp Farming Chifa
养殖面 养殖面
虾场 池 天数 病率 池 天数 病率Shrimp Farm Pond Days Sickness Rate Pond Days Sickness Rate
积(hm2) 积(hm2)Product (hm 2 ) Product (hm 2 )
数 (d) (%) 数 (d) (%)Number (d) (%) Number (d) (%)
瓦房店 5 1.5 110 <10% 5 1.5 110 90Wafangdian 5 1.5 110 <10% 5 1.5 110 90
庄河 3 1 110 0 3 1 110 100Zhuanghe 3 1 110 0 3 1 110 100
实施例11Example 11
将来自斑节对虾的WSBV如技术方法所述制备的单一灭活病毒抗原,免疫蛋鸡,收获若干鸡蛋,分离获得卵黄液,喷雾干燥法制备卵黄粉,将卵黄粉与益生素、肽聚糖和中草药粉剂制成对虾饲料添加剂:在1吨卵黄粉中加入益生素、肽聚糖和中草药粉剂各100g,搅拌均匀。The WSBV from Penaeus monodon was prepared as described in the technical method to immunize laying hens with a single inactivated virus antigen prepared as described in the technical method, harvest some eggs, separate and obtain egg yolk liquid, prepare egg yolk powder by spray drying method, combine egg yolk powder with prebiotics, peptidoglycan Prepare prawn feed additive with Chinese herbal medicine powder: add each 100g of probiotics, peptidoglycan and Chinese herbal medicine powder to 1 ton of egg yolk powder, and stir evenly.
购买专用于饲养对虾的饲料,将卵黄粉、益生素、肽聚糖及中草药调制好的添加剂按10%的量添加于基础饲料中,搅拌机搅匀后,35℃鼓风箱烘干包装。Purchase feed specially used for raising prawns, add egg yolk powder, probiotics, peptidoglycan and Chinese herbal medicine prepared additives to the basic feed in an amount of 10%, stir with a mixer, and then dry and pack in a blower box at 35°C.
于50L水族箱体中,分别饲喂斑节对虾,中国对虾,日本对虾,南美白对虾各25尾,投喂基础饲料暂养3天,分别对各水族箱体人工感染WSBV,治疗组1天两次投喂含有上述饲料添加剂的人工合成饲料,投喂5天,对照组继续投喂基础饲料,对照组发病率均为95%以上,治疗组发病率均在5~8%之间。In a 50L aquarium, feed 25 each of Penaeus monodon, Penaeus chinensis, Penaeus japonicus, and Penaeus vannamei, and feed them with basic feed for 3 days, artificially infect each aquarium with WSBV, and treat the group for 1 day The synthetic feed containing the above-mentioned feed additives was fed twice for 5 days, and the control group continued to be fed with basic feed.
实施例12Example 12
虾池面积20亩,水深1米,放苗(斑节对虾)22万尾,40天后,发生暴发性病毒白斑。第一天死虾90多尾,第二天增至近300尾。采用以下措施:外用免疫卵黄液(2mg/L)全池泼洒,内服含15%卵黄粉的人工配合饲料,连用8天。用药后第3天死虾减少,至第5天仅发现10多尾死虾,第7天恢复正常。The area of the shrimp pond is 20 mu, the water depth is 1 meter, and 220,000 seedlings (Penaeus monodon) are released. After 40 days, an outbreak of viral white spot occurs. There were more than 90 dead shrimp on the first day, and nearly 300 on the second day. Take the following measures: external use of immune egg yolk liquid (2mg/L) is splashed in the whole pool, and artificial compound feed containing 15% egg yolk powder is taken orally for 8 days. The number of dead shrimps decreased on the 3rd day after the medication, and only more than 10 dead shrimps were found on the 5th day, and returned to normal on the 7th day.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100206918A CN100443502C (en) | 2004-06-05 | 2004-06-05 | A kind of yolk immunoglobulin for preventing and treating prawn virus disease and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100206918A CN100443502C (en) | 2004-06-05 | 2004-06-05 | A kind of yolk immunoglobulin for preventing and treating prawn virus disease and its preparation method and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1583792A true CN1583792A (en) | 2005-02-23 |
CN100443502C CN100443502C (en) | 2008-12-17 |
Family
ID=34600582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100206918A Expired - Fee Related CN100443502C (en) | 2004-06-05 | 2004-06-05 | A kind of yolk immunoglobulin for preventing and treating prawn virus disease and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100443502C (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101862444A (en) * | 2010-06-11 | 2010-10-20 | 浙江大学 | Application of Interleukin 2 in Preparation of Anti-White Spot Syndrome of Shrimp |
CN102308914A (en) * | 2011-07-25 | 2012-01-11 | 大连赛姆生物工程技术有限公司 | Animal dietotherapy IgY whole egg pulp paste preparation and its preparation method |
CN101455235B (en) * | 2009-01-07 | 2012-12-26 | 大连理工大学 | Special yolk antibody preparation for fruit fresh-keeping, preparation method and use thereof |
CN104725504A (en) * | 2015-03-31 | 2015-06-24 | 华中农业大学 | Macrobranchium rosenbergii nodavirus capsid protein egg yolk antibody and application thereof |
CN105126101A (en) * | 2015-10-16 | 2015-12-09 | 扬州大学 | Microcapsule feed additive resisting to litopenaeus vannamei pathogenic vice hemolysis vibrio |
CN105166574A (en) * | 2015-10-16 | 2015-12-23 | 扬州大学 | Microencapsulated feed for resisting vibriosis of prawn larvae |
CN109198267A (en) * | 2018-09-29 | 2019-01-15 | 扬州大学 | The compound additive and its preparation method and purposes of anti-Macrobrachium rosenbergii larvae enterobacteria disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05255113A (en) * | 1992-03-16 | 1993-10-05 | Taiyo Kagaku Co Ltd | Specific antibody and shrimp infectious disease-controlling composition compounded with the same |
KR20030069506A (en) * | 2002-02-21 | 2003-08-27 | 주식회사 리앤조바이오텍 | Anti-white spot syndrome virus igy |
JP2004041005A (en) * | 2002-07-08 | 2004-02-12 | Gen Corp:Kk | White spotting disease-resistible composition |
KR100489617B1 (en) * | 2002-09-24 | 2005-05-17 | 주식회사 단바이오텍 | Soluble antibody protein for prophylaxis and treatment of white spot syndrome virus infection, eggs containing thereof and method for producing thereof |
-
2004
- 2004-06-05 CN CNB2004100206918A patent/CN100443502C/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101455235B (en) * | 2009-01-07 | 2012-12-26 | 大连理工大学 | Special yolk antibody preparation for fruit fresh-keeping, preparation method and use thereof |
CN101862444A (en) * | 2010-06-11 | 2010-10-20 | 浙江大学 | Application of Interleukin 2 in Preparation of Anti-White Spot Syndrome of Shrimp |
CN101862444B (en) * | 2010-06-11 | 2013-07-17 | 浙江大学 | Application of interleukin 2 in preparing preparation for resisting prawn white spot syndrome virus |
CN102308914A (en) * | 2011-07-25 | 2012-01-11 | 大连赛姆生物工程技术有限公司 | Animal dietotherapy IgY whole egg pulp paste preparation and its preparation method |
CN104725504A (en) * | 2015-03-31 | 2015-06-24 | 华中农业大学 | Macrobranchium rosenbergii nodavirus capsid protein egg yolk antibody and application thereof |
CN104725504B (en) * | 2015-03-31 | 2018-10-30 | 华中农业大学 | A kind of Macrobrachium rosenbergii open country field viral capsid proteins Yolk antibody and its application |
CN105126101A (en) * | 2015-10-16 | 2015-12-09 | 扬州大学 | Microcapsule feed additive resisting to litopenaeus vannamei pathogenic vice hemolysis vibrio |
CN105166574A (en) * | 2015-10-16 | 2015-12-23 | 扬州大学 | Microencapsulated feed for resisting vibriosis of prawn larvae |
CN109198267A (en) * | 2018-09-29 | 2019-01-15 | 扬州大学 | The compound additive and its preparation method and purposes of anti-Macrobrachium rosenbergii larvae enterobacteria disease |
Also Published As
Publication number | Publication date |
---|---|
CN100443502C (en) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105198988B (en) | Anti-vibrio brilliant yolk antibody and preparation method thereof | |
US10653763B2 (en) | Subunit immersion vaccines for fish | |
CN102430120B (en) | Adjuvant for enhancing fish vaccine immunization effect and application thereof | |
CN1153574C (en) | Use of bacterial cell wall extracts for treating, preventing or removing protozoa or parasitism diseases | |
CN102139103B (en) | Preparation and application methods of photobacterium damsela vaccines of cynoglossus semilaevis | |
CN100443502C (en) | A kind of yolk immunoglobulin for preventing and treating prawn virus disease and its preparation method and application | |
CN102205123B (en) | Preparation method of yolk antibody sustained-release preparation for preventing gosling plague | |
CN102206257B (en) | Edwardsiella tarda immunogenic protective antigen, and related expression vector, vaccine and application | |
CN104087559A (en) | Infectious bursal disease virus, inactivated vaccine for infectious bursal disease virus and preparation method of vaccine | |
CN104840424B (en) | A kind of hypericin albumin nanoparticle Escherichia coli serum antibody compound and its preparation method and application | |
CN1569895A (en) | Yelk antibody specific for preventing pigling diarrhea and its preparing method and application | |
CN1762387A (en) | Compound bacterin vaccine for preventing and treating aquaculture animal diseases and its preparation method | |
CN108295053A (en) | Application of the schizandrin in enhancing PEDV vaccine immune responses | |
CN1943789A (en) | The DNA vaccine of an anti-infection of hepatitis C virus | |
CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal | |
CN1879880A (en) | Use of immunological stimulant compound(ISCOMs)in fish immunity by oral administration and dipping bath method | |
CN102718866B (en) | Preparation method of yolk antibody against pathogenic Aeromonas vickerii derived from pufferfish obscura | |
CN105126101A (en) | Microcapsule feed additive resisting to litopenaeus vannamei pathogenic vice hemolysis vibrio | |
Mekata | Strategy for understanding the biological defense mechanism involved in immune priming in kuruma shrimp | |
CN1477128A (en) | Preparation method of specific IgY for resisting respiratory tract infection and its combined preparation | |
CN101032596A (en) | Medicine for treating respiratory tract diseases for chickens and its preparing process | |
CN114652828B (en) | A biological product containing novel goose parvovirus and duck circovirus antigen-antibody complexes | |
CN103893424A (en) | Traditional Chinese medicine oral liquid for preventing and treating cyanomycosis of high-quality chicken and preparation method thereof | |
CN1613456A (en) | Freezing dried mycobatctericsis preparation and its preparing method and use | |
CN1657541A (en) | Preparation method of specific composite IgY for resisting Coxsackie virus myocarditis and its combined preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081217 Termination date: 20130605 |